These results follow similar findings from the companys ATTAIN-1 trial released earlier this month, which tested the drug on people who were overweight or obese without type 2 diabetes (in general, people without diabetes tend to lose more weight from GLP-1 therapy than those with diabetes)
However, the SURMOUNT-5 trial compared tirzepatide to semaglutide 2.4mg (a more potent GLP-1 agonist than liraglutide), and tirzepatide still showed superior weight loss: 20.2% vs 13.7% at 72 weeks
Cover Image Credit: Dml5050 / 123RF.com (Licensed)
Regular exercise and a balanced diet, including lean protein, fruits, vegetables, and whole grains, are key to managing type 2 diabetes and promoting weight loss
Peptide Sequence : Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val The peptide has a molecular weight of 1,646.87 g/mol(molecular formula CHNO) and features two strategic amino acid substitutionsdesigned to enhance enzymatic stability and optimize receptor interaction: position 4 substitution of methionine with norleucine (Nle) and position 7 replacement of L-phenylalanine with D-phenylalanine (D-Phe)
